With uncertainties clouding the outcome, Gokaldas Exports MD Sivaramakrishnan Ganapathi sees status quo as the base case, ...

Royalty Pharma is less exposed to MFN drug pricing risks, offering downside protection in a volatile policy environment. See ...

While platform players are going super-wide in their offering, some legal AI startups are going the other way and drilling ...

A recent White House executive order could make it harder for millions of Americans to access their lifesaving medications.

FDA’s public guidance continues to warn that, “under most circumstances,” importing drugs for personal use is unlawful, ...

The MFN EO is designed to halt what the administration calls “global freeloading” — where other developed countries benefit from U.S.-funded drug innovation at significantly lower costs.

CEO of the National Infusion Center Association argues against a drug price control policy known as “most favored nation.” ...

Yellow Corp. and its largest shareholder urged a federal appeals court panel to overturn a bankruptcy court ruling on what ...

By Melanie Whittington President Trump recently signed a new executive order advancing a “most favored nation” (MFN) approach to drug pricing. The policy would link U.S. prices for certain medicines ...

President Donald Trump issued an executive order reviving his controversial “Most Favored Nation” (MFN) drug pricing ...